Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 05, 2019
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Journal: AIDS research and human retroviruses
Published: June 07, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Journal: AIDS research and therapy
Published: May 06, 2019
Prevalence of Darunavir Resistance in the United States from 2010 to 2017.
Journal: AIDS research and human retroviruses
Published: August 28, 2018
Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.
Journal: Drugs in R&D
Published: July 12, 2018
Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
Journal: Clinical pharmacology in drug development
Published: April 26, 2018
Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
Journal: Reviews on recent clinical trials
Published: January 23, 2017
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 23, 2013
Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.
Journal: Journal of pharmaceutical sciences
Published: October 02, 2012
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
Journal: The Journal of infectious diseases
Published: August 17, 2012
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.
Journal: Hepatology (Baltimore, Md.)
Published: January 12, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026